Nordic Study Uncovers a New Minimally Invasive Biomarker for Low-Risk Mantle Cell Lymphoma

The treatment landscape for mantle cell lymphoma (MCL) is shifting toward more targeted therapies and potentially away from chemotherapy. While some patients present with indolent disease, others have highly aggressive MCL. Today, aggressive disease is typically characterized by TP53 mutations, a high proliferation index, and blastoid morphology. However, reliable biomarkers for identifying indolent MCL have been lacking. At ASH 2025, Ingrid Glimelius from Uppsala University presented data from a Nordic study demonstrating a promising, minimally invasive biomarker with potential clinical value for stratifying low-risk MCL.